Beyond RCHOP: A blueprint for diffuse large B cell lymphoma research

Grzegorz S Nowakowski, Kristie A. Blum, Brad S. Kahl, Jonathan W. Friedberg, Lawrence Baizer, Richard F. Little, David G. Maloney, Laurie H. Sehn, Michael E. Williams, Wyndham H. Wilson, John P. Leonard, Sonali M. Smith

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Diffuse large B cell lymphoma (DLBCL) comprises multiple molecular and biological subtypes, resulting in a broad range of clinical outcomes. With standard chemoimmunotherapy, there remains an unacceptably high treatment failure rate in certain DLBCL subsets: activated B cell (ABC) DLBCL, double-hit lymphoma defined by the dual translocation of MYC and BCL2, dual protein-expressing lymphomas defined by the overexpression of MYC and BCL2, and older patients and those with central nervous system involvement. The main research challenges for DLBCL are to accurately identify molecular subsets and to determine if specific chemotherapy platforms and targeted agents offer differential benefit. The ultimate goal should be to maximize initial cure rates to improve long-termsurvival while minimizing toxicity. In particular, a frontline trial should focus on biologically defined risk groups not likely to be cured with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (R-CHOP). An additional challenge is to develop effective and personalized strategies in the relapsed setting, for which there is no current standard other than autologous stem cell transplantation, which benefits a progressively smaller proportion of patients. Relapsed/refractory DLBCL is the ideal setting for testing novel agents and new biomarker tools and will require a national call for biopsies to optimize discovery in this setting. Accordingly, the development of tools with both prognostic and predictive utility and the individualized application of new therapies should be the main priorities. This report identifies clinical research priorities for critical areas of unmet need in this disease.

Original languageEnglish (US)
Article numberdjw257
JournalJournal of the National Cancer Institute
Volume108
Issue number12
DOIs
StatePublished - Dec 1 2016

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Research
Proto-Oncogene Proteins c-bcl-2
Lymphoma
B-Lymphocyte Subsets
Stem Cell Transplantation
Vincristine
Prednisone
Treatment Failure
Doxorubicin
Cyclophosphamide
B-Lymphocytes
Central Nervous System
Biomarkers
Biopsy
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Nowakowski, G. S., Blum, K. A., Kahl, B. S., Friedberg, J. W., Baizer, L., Little, R. F., ... Smith, S. M. (2016). Beyond RCHOP: A blueprint for diffuse large B cell lymphoma research. Journal of the National Cancer Institute, 108(12), [djw257]. https://doi.org/10.1093/jnci/djw257

Beyond RCHOP : A blueprint for diffuse large B cell lymphoma research. / Nowakowski, Grzegorz S; Blum, Kristie A.; Kahl, Brad S.; Friedberg, Jonathan W.; Baizer, Lawrence; Little, Richard F.; Maloney, David G.; Sehn, Laurie H.; Williams, Michael E.; Wilson, Wyndham H.; Leonard, John P.; Smith, Sonali M.

In: Journal of the National Cancer Institute, Vol. 108, No. 12, djw257, 01.12.2016.

Research output: Contribution to journalReview article

Nowakowski, GS, Blum, KA, Kahl, BS, Friedberg, JW, Baizer, L, Little, RF, Maloney, DG, Sehn, LH, Williams, ME, Wilson, WH, Leonard, JP & Smith, SM 2016, 'Beyond RCHOP: A blueprint for diffuse large B cell lymphoma research', Journal of the National Cancer Institute, vol. 108, no. 12, djw257. https://doi.org/10.1093/jnci/djw257
Nowakowski, Grzegorz S ; Blum, Kristie A. ; Kahl, Brad S. ; Friedberg, Jonathan W. ; Baizer, Lawrence ; Little, Richard F. ; Maloney, David G. ; Sehn, Laurie H. ; Williams, Michael E. ; Wilson, Wyndham H. ; Leonard, John P. ; Smith, Sonali M. / Beyond RCHOP : A blueprint for diffuse large B cell lymphoma research. In: Journal of the National Cancer Institute. 2016 ; Vol. 108, No. 12.
@article{4bc7a55b1ecd4906977d6caf329ed061,
title = "Beyond RCHOP: A blueprint for diffuse large B cell lymphoma research",
abstract = "Diffuse large B cell lymphoma (DLBCL) comprises multiple molecular and biological subtypes, resulting in a broad range of clinical outcomes. With standard chemoimmunotherapy, there remains an unacceptably high treatment failure rate in certain DLBCL subsets: activated B cell (ABC) DLBCL, double-hit lymphoma defined by the dual translocation of MYC and BCL2, dual protein-expressing lymphomas defined by the overexpression of MYC and BCL2, and older patients and those with central nervous system involvement. The main research challenges for DLBCL are to accurately identify molecular subsets and to determine if specific chemotherapy platforms and targeted agents offer differential benefit. The ultimate goal should be to maximize initial cure rates to improve long-termsurvival while minimizing toxicity. In particular, a frontline trial should focus on biologically defined risk groups not likely to be cured with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (R-CHOP). An additional challenge is to develop effective and personalized strategies in the relapsed setting, for which there is no current standard other than autologous stem cell transplantation, which benefits a progressively smaller proportion of patients. Relapsed/refractory DLBCL is the ideal setting for testing novel agents and new biomarker tools and will require a national call for biopsies to optimize discovery in this setting. Accordingly, the development of tools with both prognostic and predictive utility and the individualized application of new therapies should be the main priorities. This report identifies clinical research priorities for critical areas of unmet need in this disease.",
author = "Nowakowski, {Grzegorz S} and Blum, {Kristie A.} and Kahl, {Brad S.} and Friedberg, {Jonathan W.} and Lawrence Baizer and Little, {Richard F.} and Maloney, {David G.} and Sehn, {Laurie H.} and Williams, {Michael E.} and Wilson, {Wyndham H.} and Leonard, {John P.} and Smith, {Sonali M.}",
year = "2016",
month = "12",
day = "1",
doi = "10.1093/jnci/djw257",
language = "English (US)",
volume = "108",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Beyond RCHOP

T2 - A blueprint for diffuse large B cell lymphoma research

AU - Nowakowski, Grzegorz S

AU - Blum, Kristie A.

AU - Kahl, Brad S.

AU - Friedberg, Jonathan W.

AU - Baizer, Lawrence

AU - Little, Richard F.

AU - Maloney, David G.

AU - Sehn, Laurie H.

AU - Williams, Michael E.

AU - Wilson, Wyndham H.

AU - Leonard, John P.

AU - Smith, Sonali M.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Diffuse large B cell lymphoma (DLBCL) comprises multiple molecular and biological subtypes, resulting in a broad range of clinical outcomes. With standard chemoimmunotherapy, there remains an unacceptably high treatment failure rate in certain DLBCL subsets: activated B cell (ABC) DLBCL, double-hit lymphoma defined by the dual translocation of MYC and BCL2, dual protein-expressing lymphomas defined by the overexpression of MYC and BCL2, and older patients and those with central nervous system involvement. The main research challenges for DLBCL are to accurately identify molecular subsets and to determine if specific chemotherapy platforms and targeted agents offer differential benefit. The ultimate goal should be to maximize initial cure rates to improve long-termsurvival while minimizing toxicity. In particular, a frontline trial should focus on biologically defined risk groups not likely to be cured with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (R-CHOP). An additional challenge is to develop effective and personalized strategies in the relapsed setting, for which there is no current standard other than autologous stem cell transplantation, which benefits a progressively smaller proportion of patients. Relapsed/refractory DLBCL is the ideal setting for testing novel agents and new biomarker tools and will require a national call for biopsies to optimize discovery in this setting. Accordingly, the development of tools with both prognostic and predictive utility and the individualized application of new therapies should be the main priorities. This report identifies clinical research priorities for critical areas of unmet need in this disease.

AB - Diffuse large B cell lymphoma (DLBCL) comprises multiple molecular and biological subtypes, resulting in a broad range of clinical outcomes. With standard chemoimmunotherapy, there remains an unacceptably high treatment failure rate in certain DLBCL subsets: activated B cell (ABC) DLBCL, double-hit lymphoma defined by the dual translocation of MYC and BCL2, dual protein-expressing lymphomas defined by the overexpression of MYC and BCL2, and older patients and those with central nervous system involvement. The main research challenges for DLBCL are to accurately identify molecular subsets and to determine if specific chemotherapy platforms and targeted agents offer differential benefit. The ultimate goal should be to maximize initial cure rates to improve long-termsurvival while minimizing toxicity. In particular, a frontline trial should focus on biologically defined risk groups not likely to be cured with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (R-CHOP). An additional challenge is to develop effective and personalized strategies in the relapsed setting, for which there is no current standard other than autologous stem cell transplantation, which benefits a progressively smaller proportion of patients. Relapsed/refractory DLBCL is the ideal setting for testing novel agents and new biomarker tools and will require a national call for biopsies to optimize discovery in this setting. Accordingly, the development of tools with both prognostic and predictive utility and the individualized application of new therapies should be the main priorities. This report identifies clinical research priorities for critical areas of unmet need in this disease.

UR - http://www.scopus.com/inward/record.url?scp=85016006845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016006845&partnerID=8YFLogxK

U2 - 10.1093/jnci/djw257

DO - 10.1093/jnci/djw257

M3 - Review article

C2 - 27986884

AN - SCOPUS:85016006845

VL - 108

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 12

M1 - djw257

ER -